Trial reportAutism research : official journal of the International Society for Autism Research2026
Effects of Cannabidiol-Rich Cannabis Oil on Facial Expression Recognition and Theory of Mind in Children With Autism Spectrum Disorder: A Randomized Clinical Trial.
Trial report in Autism research : official journal of the International Society for Autism Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
To evaluate, in a post hoc subanalysis, the effects of cannabidiol (CBD)-rich cannabis oil on facial expression recognition and theory of mind in children with autism spectrum disorder (ASD). This post hoc subanalysis included children from a double-blind, randomized, placebo-controlled trial who completed social cognition assessments at baseline and after treatment. Participants received CBD-rich cannabis oil or placebo for 12 weeks. Facial expression recognition and theory of mind were assessed using neuropsychological tasks. Between-group differences were evaluated using the Mann-Whitney U test, whereas within-group changes were assessed using the Wilcoxon signed-rank test. Nineteen Brazilian children with ASD were included (72.7% male; mean age, 7.82 years). Within-group analyses showed significant improvements in facial expression recognition (p = 0.030) and verbal theory of mind (p = 0.016) after treatment in the CBD group, whereas corresponding changes in the placebo group were not statistically significant. However, between-group comparisons showed no significant differences after treatment in facial expression recognition (p = 0.527) or verbal theory of mind (p = 0.901). Total theory of mind scores improved significantly within both groups, with no significant between-group difference (p = 0.967). Although significant within-group improvements in facial expression recognition and verbal theory of mind were observed following CBD-rich cannabis oil treatment, these changes were not significantly different from those observed with placebo. Given the small sample size and exploratory post hoc design, these findings should be interpreted cautiously and do not establish a treatment effect of CBD on social cognition in children with ASD.
trial registrationBrazilian Clinical Trials Registry (ReBEC), RBR-5wr2cqq (UTN: U1111-1261-4178), accessible at https://ensaiosclinicos.gov.br/rg/RBR-5wr2cqq.
Indexed as
Identifiers
42644517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.